Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Not yet recruiting · NCT07600151 · Registry updated 2026-05-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-20 | NCT07600151 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Sanofi | 254 |
| Universitätsklinikum Hamburg-Eppendorf | 136 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Medical Center Hamburg-Eppendorf | Hamburg | Germany | 24 |